AnaptysBio abandons eczema drug development after mid-stage trial failure-February 2024-www.financetom.com

AnaptysBio abandons eczema drug development after mid-stage trial failure

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024 6:03 AM

Dec 11 (Reuters) - AnaptysBio ( ANAB ) said on Wednesday

that it would discontinue the development of its eczema drug

after it failed to meet the main and secondary goals of a

mid-stage trial.

(Reporting by Puyaan Singh in Bengaluru; Editing by Sriraj

Kalluvila)

Previous page： Cts Insider Sold Shares Worth $836,386, According to a Recent SEC Filing Next page： LiveOne Forms Audio Advertising Partnership With Dax

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Cts Insider Sold Shares Worth $836,386, According to a Recent SEC Filing

Dec 10, 2024

03:16 PM EST, 12/10/2024 (MT Newswires) -- Kieran M O'Sullivan, Director, President & CEO, on December 06, 2024, sold 15,184 shares in Cts (CTS) for $836,386. Following the Form 4 filing with the SEC, O'Sullivan has control over a total of 375,643 shares of the company, with 375,643 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/26058/000095017024134890/xslF345X05/ownership.xml Price: 56.59, Change: +0.96, Percent Change:...

LiveOne Forms Audio Advertising Partnership With Dax

Dec 10, 2024

03:17 PM EST, 12/10/2024 (MT Newswires) -- LiveOne ( LVO ) said Tuesday it has entered into an audio advertising partnership with Dax, a digital advertising platform in the US. Under the agreement, Dax will operate as LiveOne's ( LVO ) exclusive audio advertising sales partner in the US. Other details of the deal were not disclosed. LiveOne ( LVO...

-- Theratechnologies Brief: Says Received March 2025 PDUFA Goal Date For Updated Tesamorelin F8 Formulation SBLA

Dec 10, 2024

03:15 PM EST, 12/10/2024 (MT Newswires) -- Price: 2.05, Change: -0.09, Percent Change: -4.21 ...

Sector Update: Consumer

Dec 10, 2024

03:21 PM EST, 12/10/2024 (MT Newswires) -- Consumer stocks were higher late Tuesday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) increasing 0.6% and the Consumer Discretionary Select Sector SPDR Fund (XLY) up 0.3%. Redbook US same-store sales rose by 4.2% from a year earlier in the week ended Dec. 7, slower than a 7.4% year-over-year increase in...